These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 35639264)
1. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer. Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment. Wu R; Sarkar J; Tokumaru Y; Takabe Y; Oshi M; Asaoka M; Yan L; Ishikawa T; Takabe K Am J Cancer Res; 2022; 12(2):504-520. PubMed ID: 35261783 [TBL] [Abstract][Full Text] [Related]
3. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863 [TBL] [Abstract][Full Text] [Related]
4. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients. Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427 [TBL] [Abstract][Full Text] [Related]
5. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098 [TBL] [Abstract][Full Text] [Related]
6. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer. Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202 [TBL] [Abstract][Full Text] [Related]
7. High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma. Ramos-Santillan V; Oshi M; Nelson E; Endo I; Takabe K World J Oncol; 2024 Apr; 15(2):257-267. PubMed ID: 38545476 [TBL] [Abstract][Full Text] [Related]
8. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment. Gandhi S; Oshi M; Murthy V; Repasky EA; Takabe K Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071012 [TBL] [Abstract][Full Text] [Related]
9. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208 [TBL] [Abstract][Full Text] [Related]
10. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer. Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984 [TBL] [Abstract][Full Text] [Related]
11. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer. Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329 [TBL] [Abstract][Full Text] [Related]
12. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy. Oshi M; Gandhi S; Huyser MR; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Endo I; Takabe K Am J Cancer Res; 2021; 11(9):4421-4437. PubMed ID: 34659896 [TBL] [Abstract][Full Text] [Related]
13. High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. Wu R; Patel A; Tokumaru Y; Asaoka M; Oshi M; Yan L; Ishikawa T; Takabe K Breast Cancer Res Treat; 2022 May; 193(1):49-63. PubMed ID: 35249172 [TBL] [Abstract][Full Text] [Related]
14. E2F target score is associated with cell proliferation and survival of patients with hepatocellular carcinoma. Chida K; Oshi M; Roy AM; Yachi T; Nara M; Yamada K; Matsuura O; Hashizume T; Endo I; Takabe K Surgery; 2023 Aug; 174(2):307-314. PubMed ID: 37198038 [TBL] [Abstract][Full Text] [Related]
15. High Nelson ED; Benesch MG; Wu R; Ishikawa T; Takabe K Am J Cancer Res; 2024; 14(1):227-242. PubMed ID: 38323277 [TBL] [Abstract][Full Text] [Related]
16. Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells. Pakravan K; Mossahebi-Mohammadi M; Ghazimoradi MH; Cho WC; Sadeghizadeh M; Babashah S J Transl Med; 2022 Dec; 20(1):559. PubMed ID: 36463188 [TBL] [Abstract][Full Text] [Related]
17. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer. Oshi M; Patel A; Wu R; Le L; Tokumaru Y; Yamada A; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K NPJ Breast Cancer; 2022 Aug; 8(1):92. PubMed ID: 35945417 [TBL] [Abstract][Full Text] [Related]
18. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer. Schulze A; Oshi M; Endo I; Takabe K Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143224 [No Abstract] [Full Text] [Related]
19. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer. Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K Res Sq; 2024 Mar; ():. PubMed ID: 38585981 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer in adolescents and young adults has a specific biology and poor patient outcome compared with older patients. Oshi M; Yamada A; Gandhi S; Wu R; Sasamoto M; Yamamoto S; Narui K; Ishikawa T; Takabe K; Endo I ESMO Open; 2024 Nov; 9(11):103737. PubMed ID: 39405895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]